Tubing (recreation)

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Retrieved on: 
Friday, April 5, 2024
Choline, Plasma, Liver, Nutritional science, Route of administration, Liver disease, Steatosis, Short bowel syndrome, Metabolism, Patient, Choline chloride, Cancer, ESPEN, Parenteral nutrition, Adolescence, Liver injury, Hepatology, Tubing (recreation), Fibrosis, Guideline, Society, Therapy, Copenhagen University Hospital, Safety, Pharmacokinetics, PN, FDA, ASPEN, Rigshospitalet, Food, Feeding tube, Extractive metallurgy

IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.

Key Points: 
  • IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.
  • The Company plans to advance the development of IV Choline Chloride as a source of choline for adult and adolescent patients on long-term PN.
  • The FDA has granted IV Choline Chloride Orphan Drug Designation for the prevention of choline deficiency in PN patients.
  • “We look forward to advancing the clinical development of IV Choline Chloride, which we believe has the potential to become the first FDA approved IV choline therapy for patients dependent on PN.

Navigating Birth Control: Expert Advice from Dr. Bana Kashani, OB-GYN

Retrieved on: 
Friday, March 29, 2024
Women, Other Communications, Baby, Maternity, Communications, Practice Management, Family, Health, Consumer, General Health, Birth, Pregnancy, Infertility, Q&A, Intrauterine device, Condom, Menstrual cycle, Sterilization, IUD, Ovulation, Research, Fertility, Pelvic inflammatory disease, Hormonal contraception, Tubing (recreation), STI, Woman, USB On-The-Go, Birth control

In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.

Key Points: 
  • In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.
  • “When choosing a birth control method, it's essential to consider factors such as efficacy, convenience, side effects, and personal preferences.
  • Dr. Kashani sheds light on various birth control methods in the following Q&A:
    What are the different types of birth control methods available?
  • There is limited evidence to suggest that using birth control methods for an extended period negatively impacts fertility.

Global Enteral Feeding Devices Market Insights 2024-2029 with Avanos Medical and B. Braun Melsungen Leading through Substantial R&D Investments - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Health, Medical Devices, Other Health, Hospital, Cardiology, Incidence, Enterostomy, Neurology, Conditional sentence, Growth, Prevalence, Obesity, Esophagitis, DSM-IV codes, Patient, Research, GI, Cancer, HEN, Crohn's disease, Ageing, Parenteral nutrition, Syringe, Diet, Gastrointestinal disease, Investment, Malnutrition, Safety, IBS, Dysphagia, USD, Avanos Medical, Tubing (recreation), Pediatrics, PEG

The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.

Key Points: 
  • The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.
  • Leading firms such as Avanos Medical and B. Braun Melsungen distinguish themselves through substantial research and development (R&D) investments, forming strategic alliances, and initiatives to increase their market share.
  • The enteral feeding devices market is set for sustained growth, driven by healthcare advancements and a global emphasis on chronic disease management and nutritional support.
  • North America, particularly the United States and Canada, leads in the enteral feeding devices market.

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Retrieved on: 
Wednesday, March 6, 2024
FDA, ICSI, IVF, Supreme Court of Alabama, Woman, Infertility, Female, Fertilisation, Patient, Tubing (recreation)

ATLANTA, March 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces the first commercial procedure using its FemaSeed intratubal insemination product.

Key Points: 
  • “FemaSeed presents an important advancement in women’s health with the availability of FemaSeed, a cost-effective and potentially safer alternative to other traditional infertility treatments,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “This first commercial application of the technology marks a pivotal moment in reshaping female infertility management, particularly in light of the recent legal rulings on frozen embryos by the Alabama Supreme Court.
  • Engineered to precisely deliver sperm into the fallopian tube, the site of conception, FemaSeed enables reliable and safe fertilization.
  • Dr. Andrew Wagner, Women’s OB-GYN PC, Saginaw, Michigan, who completed the first in-office commercial procedure, stated, “This marks a pivotal moment for women pursuing a reliable, readily available frontline alternative for infertility.

Flinn Foundation Names Leadership of Arizona’s Statewide Bioscience Committee

Retrieved on: 
Tuesday, February 27, 2024
Philanthropy, Health, Foundation, General Health, Research, Science, Biotechnology, Tubing (recreation), Public policy, Growth, Entrepreneurship, Rural health, Education, STEM, Roadmap, Arizona State Legislature, Public health, Associate, Arizona Center, Medical imaging, ASU, SPIE, University, Private sector, Ovarian cancer, Biomedical engineering, Policy, Biological engineering, National Advisory Council (India), Workforce, Committee, Management

The committee, administered by the Flinn Foundation, is the statewide leadership group responsible for overseeing Arizona’s Bioscience Roadmap, the long-term strategic plan to guide the growth and development of the state’s bioscience sector.

Key Points: 
  • The committee, administered by the Flinn Foundation, is the statewide leadership group responsible for overseeing Arizona’s Bioscience Roadmap, the long-term strategic plan to guide the growth and development of the state’s bioscience sector.
  • Barton, who became a committee member in 2013, will be in a committee leadership position for the first time.
  • Over the next 18 months, the committee’s guidance will be critical in the Flinn Foundation’s planned update to Arizona’s Bioscience Roadmap—the first since 2014.
  • Carter joins a distinguished group of community and bioscience leaders who have led the committee since its inception in 2002.

Endometriosis takes almost a decade to be diagnosed in the UK — our research has revealed some of the reasons why

Retrieved on: 
Tuesday, January 30, 2024
Woman, Endometriosis, Research, Thought, Face, Knowledge, GP, Tubing (recreation), Fatigue, Mental health, Workplace, Head, Nursing, Disease, Pressure, Pain, Fear, Chronic pain, Menstruation, Diagnosis, NHS

This disease causes tissue similar to the womb’s lining to grow in other places – such as the ovaries and fallopian tubes.

Key Points: 
  • This disease causes tissue similar to the womb’s lining to grow in other places – such as the ovaries and fallopian tubes.
  • Yet despite how common endometriosis is, people who have the disease still wait around eight years on average to be diagnosed.
  • Our research identified the four main challenges people faced in accessing endometriosis care:

1. Systemic sexism

  • Our participants described a health system tarred by systemic sexism.
  • Experiences were characterised by doctors and nurses not believing them or thinking they were exaggerating.
  • Almost as if it is a women’s issue that you must deal with quietly and alone.

2. Long waiting lists

  • Long waiting lists prevented participants from seeking help.
  • And, many felt resigned to pay for private healthcare if they could afford it.
  • Others chose private care because they felt waiting any longer for NHS care would have had a serious impact on their mental health.

3. Lack of treatment options

  • Participants overwhelmingly reported they felt helpless about their treatment options – even after being diagnosed.
  • As one interviewee put it:
    I feel helpless when I try to manage my pain.
  • I feel overwhelmed and I can sit there for a while and just not know what to do.


Another participant stated that the “general ‘trial and error’ approach to my treatment made me feel mistrusting of the diagnosis process and subsequent treatment”.

4. Self doubt and fatigue

  • They worried that even if they tried getting help, they wouldn’t receive the support they wanted anyway.
  • Women reported intense and overwhelming fear and helplessness, feeling drained from being forced to advocate for themselves.

Need for change

  • Our findings suggest that we need cultural change.
  • We need to de-stigmatise gynaecological health and change attitudes towards pain so that it’s no longer dismissed or normalised.
  • We also need better awareness of endometriosis and training for doctors and nurses so that diagnoses and treatment happen more quickly.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Medical Subject Headings, Diarrhea, Marketing, Platinum, INN, Peritoneum, Constipation, Fatigue, Woman, Ovarian cancer, ATC, Insomnia, Hypertension, Capsule, International, Cough, Tubing (recreation), Weakness, Headache, Disease, Nausea, Neutropenia, Language, DNA, Mouth, Cancer, Neoplasm, Thrombocytopenia, Abdomen, Dizziness, Platelet, PARP, Neutrophil, Appetite, European Medicines Agency, Back pain, Uterus, Enzyme, Select, Cell, Patient, Time, Safety, Anatomy, Anemia, Arthralgia, Vomiting, IIA, Periodic breathing

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Platinum, INN, Risk, HER2, Leukopenia, Heartburn, Woman, BRCA, Man, Nausea, DNA, Cancer, Neoplasm, Mutation, Pancreatic cancer, ADP, Prostate, Anatomy, Cell division, Cough, IIA, Diarrhea, Prostate cancer, HRD, Fatigue, Breast cancer, ATC, Platelet, Pancreas, Prednisone, Disease, Genome, Abdomen, Testosterone, PARP, Neutrophil, Bevacizumab, Appetite, Human, Anemia, Patient, Medical Subject Headings, Peritoneum, International, FIGO, Tubing (recreation), Neutropenia, Language, Castration, Dizziness, Thrombocytopenia, BRCA1, Gene, Tablet, Select, Time, Vomiting, Ovary, Prednisolone, X-ray, Ovarian cancer, Headache, BRCA2, European Medicines Agency, Indigestion, Periodic breathing, Birth control

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Trail Carbon Capture Pilot Plant Now Operational 

Retrieved on: 
Wednesday, December 20, 2023
Carbon, Tubing (recreation), Teck Resources, Acid, Recycling, Government, Glass, Form, Columbia, News, CCUS, Climate change, Carbon dioxide, CRT, TSX, CO2, Data collection, Renewable energy

TRAIL, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced the Carbon Capture Pilot Plant at its Trail Operations in southern British Columbia is now operating and successfully capturing carbon dioxide (CO2).

Key Points: 
  • TRAIL, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced the Carbon Capture Pilot Plant at its Trail Operations in southern British Columbia is now operating and successfully capturing carbon dioxide (CO2).
  • “This project is part of Teck’s ongoing work to take action on climate change and achieve our long-term goal of net-zero operations by 2050.”
    The Carbon Capture Pilot Plant separates CO2 from the Acid Plant flue gas at Trail Operations at a rate of one tonne per day and will operate through 2024 for testing and data collection purposes.
  • Teck’s Carbon Capture Utilization and Storage (CCUS) pilot project is also evaluating options for the utilization and/or storage of the captured CO2 at Trail Operations.
  • Teck acknowledges the support of the CleanBC Industry Fund for its funding contribution towards the CCUS Pilot Plant Feasibility Study and development of a CO2 storage pilot project.

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

Retrieved on: 
Monday, November 13, 2023
Research, Women, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Science, Oncology, Obstetrics and gynaecology, Woman, Epidemiology, Pathology, Gynaecology, Tubing (recreation), Verastem Oncology, Patient, Peritoneum, Neoplasm, Diagnosis, Cancer, Ovarian cancer, Partnership, Mental health, Obstetrics, Ovary, Education, Medical imaging, MD

LGSOC of the ovary, fallopian tubes, and peritoneum is a rare tumor that commonly affects younger women, with a median age of diagnosis between 45-55 years.

Key Points: 
  • LGSOC of the ovary, fallopian tubes, and peritoneum is a rare tumor that commonly affects younger women, with a median age of diagnosis between 45-55 years.
  • For many patients, LGSOC symptoms and treatment side effects have a long-lasting impact on physical and mental health.
  • “LGSOC has only recently been classified as a separate disease as compared to the more common high-grade serous ovarian cancer (HGSOC) with different epidemiology, pathology, clinical presentation, and outcomes.
  • “In addition to our work to help deliver new innovative treatment options for LGSOC, we aim to raise awareness of this distinct and different form of ovarian cancer that is under- researched and often misunderstood.